Incidences and risk factors of first-line HAART discontinuation: a limitation to the success of the “seek, test, treat, and retain” strategy?

References

• Antiretroviral Therapy Cohort Collaboration. (2013). Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002-2009. AIDS, 27, 803–813. doi:10.1097/QAD.0b013e32835cb99700002030-201303130-00014[pii]
   PubMedGoogle Scholar
• Barber, T. J., Geretti, A. M., Anderson, J., Schwenk, A., Phillips, A. N., Bansi, L., & Sabin, C. A. (2011). Outcomes in the first year after initiation of first-line HAART among heterosexual men and women in the UK CHIC Study. Antiviral Therapy, 16, 805–814. doi:10.3851/IMP1818
   PubMed Web of Science ®Google Scholar
• Beyersmann, J., Dettenkofer, M., Bertz, H., & Schumacher, M. (2007). A competing risks analysis of bloodstream infection after stem-cell transplantation using subdistribution hazards and cause-specific hazards. Statistics in Medicine, 26, 5360–5369. doi:10.1002/sim.3006
   PubMed Web of Science ®Google Scholar
• Blanco, J. R., Caro, A. M., Perez-Cachafeiro, S., Gutierrez, F., Iribarren, J. A., Gonzalez-Garcia, J., & Moreno, S. (2010). HIV infection and aging. AIDS Review, 12, 218–230.
   PubMed Web of Science ®Google Scholar
• Cambiano, V., Rodger, A. J., & Phillips, A. N. (2011).‘Test-and-treat’: The end of the HIV epidemic? Current Opinion in Infectious Diseases, 24(1), 19–26. doi:10.1097/QCO.0b013e3283422c8c
   PubMed Web of Science ®Google Scholar
• CASCADE Collaboration. (2011). Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters. Archives of Internal Medicine, 171, 1560–1569. doi:10.1001/archinternmed.2011.401
   PubMedGoogle Scholar
• Chen, R. Y., Westfall, A. O., Mugavero, M. J., Cloud, G. A., Raper, J. L., Chatham, A. G., & Saag, M. S. (2003). Duration of highly active antiretroviral therapy regimens. Clinical Infectious Diseases, 37, 714–722. doi:10.1086/377271
   PubMed Web of Science ®Google Scholar
• Cicconi, P., Cozzi-Lepri, A., Castagna, A., Trecarichi, E. M., Antinori, A., Gatti, F., & d'Arminio Monforte, A. (2010). Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort of antiretroviral-naive patients. HIV Medicine, 11(2), 104–113. doi:10.1111/j.1468-1293.2009.00750.x
   PubMed Web of Science ®Google Scholar
• Cohen, M. S., Chen, Y. Q., McCauley, M., Gamble, T., Hosseinipour, M. C., Kumarasamy, N., & Fleming, T. R. (2011). Prevention of HIV-1 infection with early antiretroviral therapy. The New England Journal of Medicine, 365, 493–505. doi:10.1056/NEJMoa1105243
   PubMed Web of Science ®Google Scholar
• d'Arminio Monforte, A., Lepri, A. C., Rezza, G., Pezzotti, P., Antinori, A., Phillips, A. N., & Moroni, M. (2000). Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naive Patients. AIDS, 14, 499–507. doi:10.1097/00002030-200003310-00005
   PubMed Web of Science ®Google Scholar
• Dieleman, J. P., Jambroes, M., Gyssens, I. C., Sturkenboom, M. C., Stricker, B. H., Mulder, W. M., & Brinkman, K. (2002). Determinants of recurrent toxicity-driven switches of highly active antiretroviral therapy. The ATHENA cohort. AIDS, 16, 737–745. doi:10.1097/00002030-200203290-00009
   PubMed Web of Science ®Google Scholar
• Elzi, L., Marzolini, C., Furrer, H., Ledergerber, B., Cavassini, M., Hirschel, B., & Battegay, M. (2010). Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008. Archives of Internal Medicine, 170(1), 57–65. doi:10.1001/archinternmed.2009.432
   PubMed Web of Science ®Google Scholar
• Floridia, M., Giuliano, M., Palmisano, L., & Vella, S. (2008). Gender differences in the treatment of HIV infection. Pharmacology Research, 58, 173–182. doi:10.1016/j.phrs.2008.07.007
   Web of Science ®Google Scholar
• Ford, N., Darder, M., Spelman, T., Maclean, E., Mills, E., & Boulle, A. (2010). Early adherence to antiretroviral medication as a predictor of long-term HIV virological suppression: Five-year follow up of an observational cohort. PLoS One, 5(5), e10460. doi:10.1371/journal.pone.0010460
   PubMed Web of Science ®Google Scholar
• Garcia de Olalla, P., Knobel, H., Carmona, A., Guelar, A., Lopez-Colomes, J. L., & Cayla, J. A. (2002). Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. Journal of Acquired Immune Deficiency Syndromes, 30(1), 105–110.
   PubMed Web of Science ®Google Scholar
• Geng, E. H., Hare, C. B., Kahn, J. O., Jain, V., Van Nunnery, T., Christopoulos, K. A., & Havlir, D. V. (2012). The effect of a “universal antiretroviral therapy” recommendation on HIV RNA levels among HIV-infected patients entering care with a CD4 count greater than 500/muL in a public health setting. Clinical Infectious Diseases, 55, 1690–1697. doi:10.1093/cid/cis750
   PubMed Web of Science ®Google Scholar
• Grambsch, P. M., & Therneau, T. M. (1994). Proportional hazards tests and diagnostics based on weighted residuals. Biometrika, 81, 515–526.
   Web of Science ®Google Scholar
• Hart, E., Curtis, H., Wilkins, E., & Johnson, M. (2007). National review of first treatment change after starting highly active antiretroviral therapy in antiretroviral-naive patients. HIV Medicine, 8, 186–191. doi:10.1111/j.1468-1293.2007.00451.x
   PubMed Web of Science ®Google Scholar
• Hayes, R., Sabapathy, K., & Fidler, S. (2011). Universal testing and treatment as an HIV prevention strategy: Research questions and methods. Current HIV Research, 9, 429–445. doi:10.2174/157016211798038515
   PubMed Web of Science ®Google Scholar
• Henard, S., Jeanmaire, E., Nguyen, Y., Yazdanpanah, Y., Cheret, A., Hoen, B., & Rabaud, C. (2012). Is total community viral load a robust predictive marker of the efficacy of the TasP strategy? Journal of Acquired Immune Deficiency Syndromes, 61, 400–402. doi:10.1097/QAI.0b013e318263a111
   PubMed Web of Science ®Google Scholar
• Keiser, O., Fellay, J., Opravil, M., Hirsch, H. H., Hirschel, B., Bernasconi, E., & Furrer, H. (2007). Adverse events to antiretrovirals in the Swiss HIV Cohort Study: Effect on mortality and treatment modification. Antiviral Therapy, 12, 1157–1164.
   PubMed Web of Science ®Google Scholar
• Keiser, O., Orrell, C., Egger, M., Wood, R., Brinkhof, M. W., Furrer, H., & Boulle, A. (2008). Public-health and individual approaches to antiretroviral therapy: Township South Africa and Switzerland compared. PLoS Medicine, 5(7), e148. doi:10.1371/journal.pmed.0050148
   Google Scholar
• Kempf, M. C., Pisu, M., Dumcheva, A., Westfall, A. O., Kilby, J. M., & Saag, M. S. (2009). Gender differences in discontinuation of antiretroviral treatment regimens. Journal of Acquired Immune Deficiency Syndromes, 52, 336–341. doi:10.1097/QAI.0b013e3181b628be
   PubMed Web of Science ®Google Scholar
• Kitahata, M. M., Gange, S. J., Abraham, A. G., Merriman, B., Saag, M. S., Justice, A. C., & Moore, R. D. (2009). Effect of early versus deferred antiretroviral therapy for HIV on survival. The New England Journal of Medicine, 360, 1815–1826. doi:10.1056/NEJMoa0807252
   PubMed Web of Science ®Google Scholar
• Knobel, H., Urbina, O., Gonzalez, A., Sorli, M. L., Montero, M., Carmona, A., & Guelar, A. (2009). Impact of different patterns of nonadherence on the outcome of highly active antiretroviral therapy in patients with long-term follow-up. HIV Medicine, 10, 364–369. doi:10.1111/j.1468-1293.2009.00696.x
   PubMed Web of Science ®Google Scholar
• Latouche, A., Allignol, A., Beyersmann, J., Labopin, M., & Fine, J. P. (2013). A competing risks analysis should report results on all cause-specific hazards and cumulative incidence functions. Journal of Clinical Epidemiology, 66, 648–653. doi:10.1016/j.jclinepi.2012.09.017
   PubMed Web of Science ®Google Scholar
• Lewden, C., Bouteloup, V., De Wit, S., Sabin, C., Mocroft, A., Wasmuth, J. C., & Chene, G. (2012). All-cause mortality in treated HIV-infected adults with CD4 >/ = 500/mm3 compared with the general population: Evidence from a large European observational cohort collaboration. International Journal of Epidemiology, 41, 433–445. doi:10.1093/ije/dyr164
   PubMed Web of Science ®Google Scholar
• Mocroft, A., Phillips, A. N., Soriano, V., Rockstroh, J., Blaxhult, A., Katlama, C., & Lundgren, J. D. (2005). Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: Increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C co-infection. AIDS Research and Human Retroviruses, 21, 743–752. doi:10.1089/aid.2005.21.743
   PubMed Web of Science ®Google Scholar
• Mocroft, A., Youle, M., Moore, A., Sabin, C. A., Madge, S., Lepri, A. C., & Phillips, A. N. (2001). Reasons for modification and discontinuation of antiretrovirals: Results from a single treatment centre. AIDS, 15, 185–194. doi:10.1097/00002030-200101260-00007
   PubMed Web of Science ®Google Scholar
• Montaner, J. S., Lima, V. D., Barrios, R., Yip, B., Wood, E., Kerr, T., & Kendall, P. (2010). Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: A population-based study. The Lancet, 376, 532–539. doi:10.1016/S0140-6736(10)60936-1
   PubMed Web of Science ®Google Scholar
• O'Brien, M. E., Clark, R. A., Besch, C. L., Myers, L., & Kissinger, P. (2003). Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort. Journal of Acquired Immune Deficiency Syndromes, 34, 407–414. doi:10.1097/00126334-200312010-00008
   PubMed Web of Science ®Google Scholar
• Palella Jr, F. J., Chmiel, J. S., Moorman, A. C., & Holmberg, S. D. (2002). Durability and predictors of success of highly active antiretroviral therapy for ambulatory HIV-infected patients. AIDS, 16, 1617–1626. doi:10.1097/00002030-200208160-00007
   PubMed Web of Science ®Google Scholar
• Park, W. B., Choe, P. G., Kim, S. H., Jo, J. H., Bang, J. H., Kim, H. B., & Choe, K. W. (2007). Early modification of initial HAART regimen associated with poor clinical outcome in HIV patients. AIDS Research and Human Retroviruses, 23, 794–800. doi:10.1089/aid.2006.0255
   PubMed Web of Science ®Google Scholar
• Prosperi, M. C., Fabbiani, M., Fanti, I., Zaccarelli, M., Colafigli, M., Mondi, A., & Di Giambenedetto, S. (2012). Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: A retrospective cohort study. BMC Infectious Diseases, 12, 296. doi:10.1186/1471-2334-12-296
   PubMed Web of Science ®Google Scholar
• Pugliese, P., Cuzin, L., Cabie, A., Poizot-Martin, I., Allavena, C., Duvivier, C., & Dellamonica, P. (2009). A large French prospective cohort of HIV-infected patients: The Nadis Cohort. HIV Medicine, 10, 504–511. doi:10.1111/j.1468-1293.2009.00719.x
   PubMed Web of Science ®Google Scholar
• Pujades-Rodriguez, M., Balkan, S., Arnould, L., Brinkhof, M. A., & Calmy, A. (2010). Treatment failure and mortality factors in patients receiving second-line HIV therapy in resource-limited countries. The Journal of the American Medical Association, 304, 303–312. doi:10.1001/jama.2010.980
   Web of Science ®Google Scholar
• Pujades-Rodriguez, M., O'Brien, D., Humblet, P., & Calmy, A. (2008). Second-line antiretroviral therapy in resource-limited settings: The experience of Medecins Sans Frontieres. AIDS, 22, 1305–1312. doi:10.1097/QAD.0b013e3282fa75b9
   PubMed Web of Science ®Google Scholar
• Smit, M., Smit, C., Cremin, I., Garnett, G. P., Hallett, T., & de Wolf, F. (2012). Could better tolerated HIV drug regimens improve patient outcome? AIDS, 26, 1953–1959. doi:10.1097/QAD.0b013e32835722bd
   PubMed Web of Science ®Google Scholar
• Sterne, J. A., May, M., Costagliola, D., de Wolf, F., Phillips, A. N., Harris, R., & Cole, S. R. (2009). Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: A collaborative analysis of 18 HIV cohort studies. The Lancet, 373, 1352–1363. doi:10.1016/S0140-6736(09)60612-7
   PubMed Web of Science ®Google Scholar
• Thompson, M. A., Mugavero, M. J., Amico, K. R., Cargill, V. A., Chang, L. W., Gross, R., & Nachega, J. B. (2012). Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: Evidence-based recommendations from an International Association of Physicians in AIDS Care panel. Annals of Internal Medicine, 156, 817–833. doi:10.7326/0003-4819-156-11-201206050-00419
   PubMed Web of Science ®Google Scholar
• USA Panel. (2013). Initiating antiretroviral therapy in treatment-naive patients – 2012 guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Retrieved from http://aidsinfo.nih.gov/contentfiles/lvguidelines/glchunk/glchunk_10.pdf
   Google Scholar
• Vo, T. T., Ledergerber, B., Keiser, O., Hirschel, B., Furrer, H., Battegay, M., & Weber, R. (2008). Durability and outcome of initial antiretroviral treatments received during 2000–2005 by patients in the Swiss HIV Cohort Study. Journal of Infectious Diseases, 197, 1685–1694. doi:10.1086/588141
   PubMed Web of Science ®Google Scholar
• Willig, J. H., Abroms, S., Westfall, A. O., Routman, J., Adusumilli, S., Varshney, M., & Mugavero, M. J. (2008). Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy. AIDS, 22, 1951–1960. doi:10.1097/QAD.0b013e32830efd79
   PubMed Web of Science ®Google Scholar
• World Health Organization. (2013). Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: Recommendations for a public health approach. pp. 93. Retrieved from http://www.who.int/hiv/pub/guidelines/arv2013/download/en/.
   Google Scholar
• Yuan, Y., L'Italien, G., Mukherjee, J., & Iloeje, U. H. (2006). Determinants of discontinuation of initial highly active antiretroviral therapy regimens in a US HIV-infected patient cohort. HIV Medicine, 7, 156–162. doi:10.1111/j.1468-1293.2006.00355.x
   PubMed Web of Science ®Google Scholar